7 results
Anti-IL6 Agents (Tocilizumab, Siltuximab) in COVID19

IL-6 activates T cells and macrophages, among other cell types (see
Total dose should ... Tocilizumab should ... respiratory tract infection ... Siltuximab #COVID19 #Pharmacology ... #Management #Medications
IDSA Recommendations for Treating Cytomegalovirus Infections in HIV-AIDS
Preventing CMV Disease:
 • CMV end-organ disease is best
., concomitant medications ... ) for 1–4 doses ... Prevention #Treatment #management ... #opportunistic ... #pharmacology
Rybelsus (oral semaglutide) - First Oral GLP-1 Agonist
Dosing:
3 mg daily x 30 days, then 7 mg
semaglutide, the same medication ... Patients should ... take any other medications ... been shown non-inferior ... semaglutide #Diabetes #Pharmacology
IDSA Recommendations for Preventing and Treating Varicella Zoster Virus (VZV) Infections in HIV-AIDS
Pre-Exposure Prevention of VZV
(Varivax™), 2 doses ... HIV-infected persons should ... Prevention #Treatment #management ... #opportunistic ... #pharmacology
Gout - Diagnosis and Management Summary

3 Conditions for Gout to Manifest:
1. Hyperuricemia
2. Monosodium urate deposition in
Diagnosis and Management ... forefoot, ankles, knees ... Diagnose concomitant infection ... NSAIDs • Low-dose ... Concomitant low-dose
IDSA Recommendations for Treating Mycobacterium Tuberculosis Infection and Disease in HIV-AIDS
Treating LTBI (to prevent TB disease)
Indications:
months or • RFB (dose ... empiric treatment should ... Prevention #Treatment #management ... #opportunistic ... #pharmacology
IDSA Recommendations for Preventing and Treating Disseminated Mycobacterium Avium Complex in HIV-AIDS
Preventing 1st Episode of Disseminated
Note: Active TB should ... Prevention #Treatment #management ... #opportunistic ... #infections #HIVAIDS ... #pharmacology